United States securities and exchange commission logo

                  May 20, 2022

       N. Anthony Coles, M.D.
       Chief Executive Officer
       Cerevel Therapeutics Holdings, Inc.
       222 Jacobs Street, Suite 200
       Cambridge, MA 02141

                                                        Re: Cerevel
Therapeutics Holdings, Inc.
Statement on Form S-3
                                                            Filed May 10, 2022
                                                            File No. 333-264812

       Dear Dr. Coles:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

             Please contact Michael Davis at 202-551-4385 or Christopher
Edwards at 202-551-
       6761 with any questions.


                  Division of Corporation Finance

                  Office of Life Sciences
       cc:                                              Arthur R. McGivern